A new handheld device uses AI to screen for skin cancer: Dermatologist explains how it works

Medical Economics October 25, 2024
Grace Halsey

Key Takeaways

• Primary care clinicians are typically the first to assess suspicious skin lesions, deciding on monitoring or specialist referral.
• DermaSensor, an FDA-approved AI device, aids primary care by scanning lesions and suggesting “Investigate Further” or “Monitor.”
• The device aims to minimize unnecessary referrals for benign lesions, enhancing decision-making in primary care.
• Dermatologist Rebecca Hartman highlights the device’s sensitivity and specificity, underscoring its utility in primary care settings.

DermaSensor is a new FDA-approved handheld that is designed to scan and assess skin lesions in the primary care clinical setting. Rebecca Hartman, MD, MPH, describes how it works.

The first health care professional to examine a skin lesion that appears suspicious to a patient is most frequently the primary...

Today's Sponsors

Today's Sponsor